Behçet's syndrome is a form of autoimmune vasculitis marked by widespread and sometimes life-threatening cardiovascular ...

Vasculitis is a rare but serious condition that involves inflammation of the blood vessels. This inflammation can affect ...

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

An 18-year-old racing driver said he felt like he was living in "limbo" while waiting for test results following health ...

Individuals with restrictive eating behaviors, developmental disorders, or malabsorption are particularly at risk.

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...

The National Agency for Food and Drug Administration and Control, NAFDAC, yesterday issued a nationwide alert to healthcare ...

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< ...

Ocugen Inc. (NASDAQ:OCGN) shares fell 5% Tuesday following the announcement of 12-month data from its Phase 2 ArMaDa clinical ...

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...

Hematochezia was the most common symptom in patients with AAV and GI manifestations, and other symptoms included abdominal pain, fever, diarrhea, and vomiting.

A patient developed granulomatosis with polyangiitis (GPA), a type of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), following a long-standing history of systemic lupus ...